RNA sequencing has become an essential tool for understanding gene expression and identifying biomarkers for disease. Most sequencing methods require converting RNA into DNA before analysis, which can introduce biases and miss important molecular details. A newer approach called direct RNA sequencing allows scientists to read RNA molecules in their natural form, preserving critical information such as chemical modifications.

Researchers at the Johannes Gutenberg University Mainz evaluated recent advances in direct RNA sequencing using Nanopore technology. Earlier versions of this method faced limitations, including lower accuracy and throughput, which made it difficult to apply in clinical settings.

The team tested an updated sequencing chemistry called RNA004, along with improved computational models designed to detect specific RNA modifications. These included pseudouridine and N6-methyladenosine, two important chemical changes that can influence how RNA functions inside cells.

To assess performance, the researchers analyzed a variety of samples, including cultured cells, synthetic RNA molecules, and human blood. The updated system showed clear improvements in both sequencing accuracy and throughput, making it more practical for large scale and clinical applications.

One of the most significant outcomes was the ability to detect RNA modifications at specific sites with greater confidence. This is important because RNA modifications play key roles in regulating gene expression and are increasingly linked to disease.

The researchers also demonstrated a clinical application of the technology. They examined a patient with mutations in the METTL5 gene, which is involved in RNA methylation. Using direct RNA sequencing, they were able to confirm a loss of RNA methylation in the patient’s cells, highlighting the potential of this approach for diagnosing molecular defects.

In addition to diagnostics, the study explored how direct RNA sequencing could be used to evaluate RNA based therapeutics. The results suggest that while the technology is promising, there are still challenges to address for routine quality control and regulatory use.

Overall, the work shows that combining improved sequencing chemistry with advanced computational models can significantly enhance the performance of direct RNA sequencing. These advances bring the technology closer to routine use in clinical diagnostics and biomarker discovery.